Unmet needs in psychiatry and emerging novel pharmacological agents

References

• National Institute of Mental Health. Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Study. http://www.nimh.nih.gov/trials/practical/stard/index.shtml. Accessed April 27, 2012.
   Google Scholar
• National Institute of Mental Health. Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). http://www.nimh.nih.gov/trials/practical/step-bd/index.shtml. Accessed April 27, 2012.
   Google Scholar
• Stephan KE, Baldeweg T, Friston KJ. Synaptic plasticity and dysconnection in schizophrenia. Biol Psychiatry 2006; 59(10): 929–39.
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Singh J, Manji HK. Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry 2006; 59(11): 1006–20.
   PubMed Web of Science ®Google Scholar
• Meldrum BS. Glutamate as a Neurotransmitter in the Brain: Review of Physiology and Pathology. J Nutr 2000; 130: 1007–15.
   PubMed Web of Science ®Google Scholar
• Zarate C Jr, Machado-Vieira R, Henter I, Ibrahim L, Diazgranados N, Salvadore G. Glutamatergic Modulators: The Future of Treating Mood Disorders? Harv Rev Psychiatry. 2010; 18(5): 293–303.
   Web of Science ®Google Scholar
• Miller AH, Maletic V, Raison CL. Inflammation and its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression. Biol Psychiatry 2009; 65: 732–41.
   PubMed Web of Science ®Google Scholar
• Tilleux S, Hermans E. Neuroinflammation and regulation of glial glutamate uptake in neurological disorders. J Neurosci Res 2007; 85(10): 2059–70.
   PubMed Web of Science ®Google Scholar
• Ida T, Hara M, Nakamura Y, Kozaki S, Tsunoda S, Ihara H. Cytokine-induced enhancement of calcium-dependent glutamate release from astrocytes mediated by nitric oxide. Neurosci Lett 2008; 27; 432(3): 232–6.
   Google Scholar
• Pitt D, Nagelmeier IE, Wilson HC, Raine CS. Glutamate uptake by oligodendrocytes: Implications for excitotoxicity in multiple sclerosis. Neurology 2003; 28; 61(8): 1113–20.
   Google Scholar
• Bezzi P, Domercq M, Brambilla L, Galli R, Schols D, De Clercq E, et al. A. CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity. Nat Neurosci 2001; 4(7): 702–10.
   PubMed Web of Science ®Google Scholar
• Scapagnini G, Davinelli S, Drago F, de Lorenzo A, Oriani G. Antioxidants as antidepressants: fact or fiction? CNS Drugs 2012; 26(6): 477–90.
   PubMed Web of Science ®Google Scholar
• Costa BM, Irvine MW, Fang G, Eaves RJ, Mayo-Martin MB, Skifter DA, et al. A novel family of negative and positive allosteric modulators of NMDA receptors. J Pharmacol Exp Ther 2010; 335(3): 614–21.
   PubMed Web of Science ®Google Scholar
• Lang UE, Borgwardt S. Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies. Cell Physiol Biochem 2013; 31(6): 761–77.
   PubMed Web of Science ®Google Scholar
• Alt A, Nisenbaum ES, Bleakman D, Witkin JM. A role for AMPA receptors in mood disorders. Biochem Pharmacol 2006; 71(9): 1273–88.
   PubMed Web of Science ®Google Scholar
• Lynch G. Glutamate-based therapeutic approaches: ampakines. Curr Opin Pharmacol 2006; 6(1): 82–8.
   Web of Science ®Google Scholar
• http://clinicaltrials.gov/ct2/show/NCT00986479
   Google Scholar
• http://clinicaltrials.gov/ct2/show/NCT01234558.
   Google Scholar
• Brennan BP, Hudson JI, Jensen JE, McCarthy J, Roberts JL, Prescot AP, et al. Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole. Neuropsychopharmacology 2010; 35(3): 834–46.
   PubMed Web of Science ®Google Scholar
• Sanacora G, Kendell SF, Levin Y, Simen AA, Fenton LR, Coric V, et al. Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry 2007; 61(6): 822–5.
   PubMed Web of Science ®Google Scholar
• Chaki S, Ago Y, Palucha-Paniewiera A, Matrisciano F, Pilc A. mGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants. Neuropharmacology 2013; 66:40–52.
   PubMed Web of Science ®Google Scholar
• Wierońska JM, Pilc A. Metabotropic glutamate receptors in the tripartite synapse as a target for new psychotropic drugs. Neurochem Int 2009; 55(1–3): 85–97.
   Web of Science ®Google Scholar
• Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000; 47(4): 351–4.
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Quiroz JA, Singh JB, Denicoff KD, De Jesus G, Luckenbaugh DA, et. al. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry 2005; 57(4): 430–2.
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63(8): 856–64.
   PubMed Web of Science ®Google Scholar
• Karolewicz B, Cetin M, Aricioglu F. Beyond the glutamate N-methyl D-aspartate receptor in major depressive disorder: the mTOR signaling pathway. Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology 2011; 21(1): 1–6.
   Web of Science ®Google Scholar
• Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010; 329(5994): 959–64.
   PubMed Web of Science ®Google Scholar
• Duman RS, Li N, Liu RJ, Duric V, Aghajanian G. Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 2012; 62(1): 35–41.
   PubMed Web of Science ®Google Scholar
• Hallak JEC, Oliveira JPM, Abrao J, Evora PR, Zuardi AW, Crippa JA, et al. Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized, double-blind, placebo-controlled trial. JAMA Psychiatry 2013; 70(7): 668–76.
   Web of Science ®Google Scholar
• Dhami K, MacKay M, Maia-de-Oliveira JP, Hallak J, Todd K, Baker G, Dursun S. Novel targets for development of drugs for treating schizophrenia: focus on glycine, d-serine and nitric oxide. Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology 2013; 23(2): 129–37.
   Web of Science ®Google Scholar
• Jaffrey SR, Snyder SH. Nitric oxide: a neural messenger. Annu Rev Cell Dev Biol 1995; 11: 417–40.
   PubMed Web of Science ®Google Scholar
• Pinkham A, Loughead J, Ruparel K, Wu WC, Overton E, Gur R, et al. Resting quantitative cerebral blood flow in schizophrenia measured by pulsed arterial spin labeling perfusion MRI. Psychiatry Res 2011; 194(1): 64–72.
   Web of Science ®Google Scholar
• http://www.bloomberg.com/news/2013-05-23/j-j-sees-10-products-submitted-for-approval-by-2017.html
   Google Scholar